Desmethylglycitein (Synonyms: 6-hydroxy Daidzein, 6,7,4’-THIF) |
Catalog No.GC38482 |
데스메틸글리시테인(4',6,7-트리하이드록시이소플라본)은 daidzein의 대사산물로, 항산화 및 항암 활성이 있는 Glycine max에서 공급됩니다. Desmethylglycitein은 생체 내에서 CDK1 및 CDK2에 직접 결합하여 CDK1 및 CDK2 활성을 억제합니다. 데스메틸글리시테인은 태양 자외선(sUV)에 의해 유도된 매트릭스 매트릭스 메탈로프로테이나제 1(MMP1)에 대한 단백질 키나제 C(PKC)α의 직접적인 억제제입니다. 데스메틸글리시테인은 세포질에서 ATP 경쟁 방식으로 PI3K에 결합하여 PI3K 및 다운스트림 신호 전달 캐스케이드의 활성을 억제하여 3T3-L1 지방전구세포에서 지방 생성을 억제합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 17817-31-1
Sample solution is provided at 25 µL, 10mM.
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities.Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity[1]. Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1)[2]. Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes[3].
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity [1].Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells[1].Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) [1]. Cell Viability Assay[1] Cell Line: HCT-116 cells
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system[1]. Animal Model: Female athymic nude mice subcutaneously injected with HCT-116 cells[1]
[1]. Lee DE, et al. 6,7,4'-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2. Carcinogenesis. 2011 Apr;32(4):629-35. [2]. Lim TG, et al. The daidzein metabolite, 6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1. Int J Mol Sci. 2014 Nov 19;15(11):21419-32 [3]. Seo SG, et al. A metabolite of daidzein, 6,7,4'-trihydroxyisoflavone, suppresses adipogenesis in 3T3-L1 preadipocytes via ATP-competitive inhibition of PI3K.
Average Rating: 5
(Based on Reviews and 26 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *